{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:19:10Z","timestamp":1785482350587,"version":"3.56.0"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bone.2023.116957","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T17:01:15Z","timestamp":1699981275000},"page":"116957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The role of conventional and novel PET radiotracers in assessment of myeloma bone disease"],"prefix":"10.1016","volume":"179","author":[{"given":"Mahdi","family":"Zirakchian Zadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2023.116957_bb0005","series-title":"Myeloma Bone Disease","author":"Roodman","year":"2010"},{"issue":"14","key":"10.1016\/j.bone.2023.116957_bb0010","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: from biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.bone.2023.116957_bb0020","first-page":"2667","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0025","first-page":"313","article-title":"Skeletal imaging and management of bone disease","volume":"2008","author":"Roodman","year":"2008","journal-title":"ASH Education Program Book"},{"key":"10.1016\/j.bone.2023.116957_bb0030","series-title":"Mayo Clinic Proceedings","first-page":"21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","author":"Kyle","year":"2003"},{"issue":"8","key":"10.1016\/j.bone.2023.116957_bb0035","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bone.2023.116957_bb0040","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/cncr.22678","article-title":"Economic burden of metastatic bone disease in the US","volume":"109","author":"Schulman","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0045","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cpet.2019.03.004","article-title":"Evolving roles of fluorodeoxyglucose and sodium fluoride in assessment of multiple myeloma patients: introducing a novel method of PET quantification to overcome shortcomings of the existing approaches","volume":"14","author":"Zadeh","year":"2019","journal-title":"PET Clin."},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0050","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/MNM.0000000000001528","article-title":"A review of different methods used for quantification and assessment of FDG-PET\/CT in multiple myeloma","volume":"43","author":"Zirakchian Zadeh","year":"2022","journal-title":"Nucl. Med. Commun."},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0055","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0060","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MNM.0000000000001144","article-title":"Brain glucose metabolism in patients with newly diagnosed multiple myeloma significantly decreases after high-dose chemotherapy followed by autologous stem cell transplantation","volume":"41","author":"Pourhassan Shamchi","year":"2020","journal-title":"Nucl. Med. Commun."},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0065","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MNM.0000000000001000","article-title":"Dynamics of fluorine-18-fluorodeoxyglucose uptake in the liver and its correlation with hepatic fat content and BMI","volume":"40","author":"Seraj","year":"2019","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.bone.2023.116957_bb0070","series-title":"Fludeoxyglucose (18F)","author":"Ashraf","year":"2023"},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb5000","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.blre.2016.02.003","article-title":"FDG-PET imaging in hematological malignancies","volume":"30","author":"Valls","year":"2016","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.bone.2023.116957_bb0075","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0080","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","article-title":"Value of FDG PET in the assessment of patients with multiple myeloma","volume":"184","author":"Bredella","year":"2005","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.bone.2023.116957_bb0095","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1007\/s00259-020-05182-2","article-title":"Comparison of the diagnostic performance and impact on management of 18F-FDG PET\/CT and whole-body MRI in multiple myeloma","volume":"48","author":"O. Westerland, A. Amlani, C. Kelly-Morland, M. Fraczek, K. Bailey, M. Gleeson, I. El-Najjar, M. Streetly, P. Bassett, G.J.R. Cook, V. Goh, J. Bell, I. Dregely, A. Green, R. Gu, U. Haberland, S. Jeljeli, M. Kazmi, N. Muhidun, S. Natas, R. Neji, F. Padormo, J. Spence, J.J. Stirling, M. Subesinghe, H. Verma, Z. Viney, G.s. on behalf of the Myeloma Imaging Research Group at, L. St Thomas\u2019\u2019 Hospital, L. King\u2019\u2019s College","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bone.2023.116957_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2021.808627","article-title":"18F-FDG PET\/CT and MRI in the management of multiple myeloma: a comparative review","volume":"1","author":"Mesguich","year":"2022","journal-title":"Front. Nucl. Med."},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0105","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.semnuclmed.2022.10.008","article-title":"Clinical value of FDG-PET\/CT in multiple myeloma: an update","volume":"53","author":"Bezzi","year":"2023","journal-title":"Semin. Nucl. Med."},{"issue":"23","key":"10.1016\/j.bone.2023.116957_bb0110","first-page":"5989","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00330-020-07177-x","article-title":"Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"31","author":"Han","year":"2021","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.bone.2023.116957_bb0120","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.bone.2023.116957_bb0125","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/RLU.0000000000002501","article-title":"An isolated osseous Rosai-Dorfman disease shown on FDG PET\/CT","volume":"44","author":"Zadeh","year":"2019","journal-title":"Clin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cpet.2019.03.003","article-title":"Evolving role of PET-based novel quantitative techniques in the management of hematological malignancies","volume":"14","author":"Raynor","year":"2019","journal-title":"PET Clin."},{"key":"10.1016\/j.bone.2023.116957_bb0135","series-title":"Clinical Radiation Oncology (Fourth Edition)","first-page":"206","article-title":"Chapter 11 - nuclear medicine","author":"Wong","year":"2016"},{"key":"10.1016\/j.bone.2023.116957_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11307-018-1181-3","article-title":"The evolving role of FDG-PET\/CT in the diagnosis, staging, and treatment of breast cancer","volume":"21","author":"Paydary","year":"2019","journal-title":"Mol. Imaging Biol."},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cpet.2019.06.004","article-title":"The evolving role of PET-based novel quantitative techniques in the interventional radiology procedures of the liver","volume":"14","author":"Seraj","year":"2019","journal-title":"PET Clin."},{"key":"10.1016\/j.bone.2023.116957_bb0150","series-title":"SUV Max of 2.5 Should Not Be Embraced as a Magic Threshold for Separating Benign from Malignant Lesions","author":"Kwee","year":"2013"},{"issue":"2","key":"10.1016\/j.bone.2023.116957_bb0155","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1148\/rg.2016150102","article-title":"Role of optimal quantification of FDG PET imaging in the clinical practice of radiology","volume":"36","author":"Ziai","year":"2016","journal-title":"RadioGraphics"},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0160","first-page":"204","article-title":"Variation and repeatability of measured standardized uptake values depending on actual values: a phantom study","volume":"7","author":"Kaneta","year":"2017","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0165","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnmt.115.161745","article-title":"Influence of statistical fluctuation on reproducibility and accuracy of SUVmax and SUVpeak: a phantom study","volume":"43","author":"Akamatsu","year":"2015","journal-title":"J. Nucl. Med. Technol."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0170","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13550-019-0569-7","article-title":"SUV variability in EARL-accredited conventional and digital PET","volume":"9","author":"Koopman","year":"2019","journal-title":"EJNMMI Res."},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0175","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.bone.2023.116957_bb0180","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/MNM.0000000000001573","article-title":"Prognostic significance of conventional and volumetric PET parameters with and without partial volume correction in the assessment of head and neck squamous cell carcinoma","volume":"43","author":"Zirakchian Zadeh","year":"2022","journal-title":"Nucl. Med. Commun."},{"issue":"6","key":"10.1016\/j.bone.2023.116957_bb0185","first-page":"407","article-title":"Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing\/refractory non-hodgkin lymphoma following radioimmunotherapy","volume":"8","author":"Taghvaei","year":"2018","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0190","first-page":"248","article-title":"Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease","volume":"9","author":"Seraj","year":"2019","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"supplement 1","key":"10.1016\/j.bone.2023.116957_bb0195","first-page":"1359","article-title":"FDG-PET response to nivolumab is predictive of tumor progression and survival in non-small cell lung cancer patients","volume":"61","author":"Seraj","year":"2020","journal-title":"Soc. Nuclear Med."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0200","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better?","volume":"52","author":"Im","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13014-019-1236-x","article-title":"Metabolic parameters of sequential 18F-FDG PET\/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation","volume":"14","author":"Li","year":"2019","journal-title":"Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12149-022-01812-x","article-title":"Prognostic value of semi-quantitative parameters of (18)F-FDG PET\/CT in newly diagnosed multiple myeloma patients","volume":"37","author":"Wan","year":"2023","journal-title":"Ann. Nucl. Med."},{"issue":"8","key":"10.1016\/j.bone.2023.116957_bb0215","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","article-title":"Assessment of total lesion glycolysis by (18)F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma","volume":"23","author":"McDonald","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0220","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00330-020-07412-5","article-title":"Critical role of PET\/CT-based novel quantitative techniques for assessing global disease activity in multiple myeloma and other hematological malignancies: why it is time to abandon reliance on examining focal lesions","volume":"31","author":"Taghvaei","year":"2020","journal-title":"Eur. Radiol."},{"issue":"1046","key":"10.1016\/j.bone.2023.116957_bb0225","doi-asserted-by":"crossref","first-page":"20140119","DOI":"10.1259\/bjr.20140119","article-title":"Partial-volume effect correction in positron emission tomography brain scan image using super-resolution image reconstruction","volume":"88","author":"Meechai","year":"2015","journal-title":"Br. J. Radiol."},{"issue":"supplement 1","key":"10.1016\/j.bone.2023.116957_bb0230","first-page":"190","article-title":"Quantification of the total bone marrow activity with FDG-PET in multiple myeloma before and after treatment: comparison with a control group","volume":"58","author":"Zirakchian Zadeh","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"supplement 1","key":"10.1016\/j.bone.2023.116957_bb0235","first-page":"1017","article-title":"Global assessment of PET tracer uptake in the skeleton using CT segmentation: a novel approach to quantification of disease activity and whole body metabolism","volume":"58","author":"Acosta-Montenegro","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0240","doi-asserted-by":"crossref","first-page":"16429","DOI":"10.1038\/s41598-019-52740-2","article-title":"Proposal for a quantitative 18F-FDG PET\/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma","volume":"9","author":"Takahashi","year":"2019","journal-title":"Sci. Rep."},{"issue":"9, supplement 1","key":"10.1016\/j.bone.2023.116957_bb0245","first-page":"99","article-title":"Correlation between whole-bone marrow 18F-FDG uptake and prognostic factors in newly diagnosed multiple myeloma patients","volume":"61","author":"Zirakchian Zadeh","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0250","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MNM.0000000000001165","article-title":"Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma","volume":"41","author":"Takahashi","year":"2020","journal-title":"Nucl. Med. Commun."},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0255","first-page":"257","article-title":"Correlation of whole-bone marrow dual-time-point 18F-FDG, as measured by a CT-based method of PET\/CT quantification, with response to treatment in newly diagnosed multiple myeloma patients","volume":"10","author":"Zadeh","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"12","key":"10.1016\/j.bone.2023.116957_bb0260","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1007\/s00259-020-04768-0","article-title":"Comparison of (18)F-sodium fluoride uptake in the whole bone, pelvis, and femoral neck of multiple myeloma patients before and after high-dose therapy and conventional-dose chemotherapy","volume":"47","author":"Zirakchian Zadeh","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0265","first-page":"30","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG\u2013positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"6","key":"10.1016\/j.bone.2023.116957_bb0270","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s13244-010-0062-3","article-title":"Causes and imaging features of false positives and false negatives on F-PET\/CT in oncologic imaging","volume":"2","author":"Long","year":"2011","journal-title":"Insights Imaging"},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0275","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/hemato2040049","article-title":"New targets for PET imaging of myeloma","volume":"2","author":"Revheim","year":"2021","journal-title":"Hemato"},{"issue":"7","key":"10.1016\/j.bone.2023.116957_bb0280","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00259-015-3282-4","article-title":"Malignancy rate of biopsied suspicious bone lesions identified on FDG PET\/CT","volume":"43","author":"Adams","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bone.2023.116957_bb0285","article-title":"Fluorine-18: a new isotope for bone scanning","volume":"3","author":"Blau","year":"1962","journal-title":"J. Nuclear Med."},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0290","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jbo.2015.08.002","article-title":"The role of 18F-NaF PET\/CT in metastatic bone disease","volume":"4","author":"Araz","year":"2015","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bone.2023.116957_bb0295","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s00259-011-1904-z","article-title":"Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine\u2013a review","volume":"38","author":"Eberlein","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"10.1016\/j.bone.2023.116957_bb0300","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/MNM.0000000000000891","article-title":"Quantitative evaluation of normal spinal osseous metabolism with 18F-NaF PET\/CT","volume":"39","author":"Ayubcha","year":"2018","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.bone.2023.116957_bb0305","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12149-020-01463-w","article-title":"Assessing the feasibility of NaF-PET\/CT versus FDG-PET\/CT to detect abdominal aortic calcification or inflammation in rheumatoid arthritis patients","volume":"34","author":"Seraj","year":"2020","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.bone.2023.116957_bb0310","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1007\/s12350-020-02446-0","article-title":"Assessment of atherosclerosis in multiple myeloma and smoldering myeloma patients using 18 F-sodium fluoride PET\/CT","volume":"28","author":"Arani","year":"2021","journal-title":"J. Nucl. Cardiol."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cpet.2018.08.007","article-title":"Evolving role of MR imaging and PET in assessing osteoporosis","volume":"14","author":"Austin","year":"2019","journal-title":"PET Clin."},{"key":"10.1016\/j.bone.2023.116957_bb0320","series-title":"Seminars in Nuclear Medicine","first-page":"28","article-title":"Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate","author":"Blake","year":"2001"},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0325","first-page":"151","article-title":"Prognostic significance of (18)F-sodium fluoride in newly diagnosed multiple myeloma patients","volume":"10","author":"Zadeh","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.bone.2023.116957_bb0330","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00277-015-2410-3","article-title":"Is there any complimentary role of F-18 NaF PET\/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET\/CT and F-18 FDG NaF PET\/CT","volume":"94","author":"Ak","year":"2015","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.bone.2023.116957_bb0335","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00259-014-2721-y","article-title":"PET\/CT studies of multiple myeloma using (18)F-FDG and (18)F-NaF: comparison of distribution patterns and tracers\u2019 pharmacokinetics","volume":"41","author":"Sachpekidis","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0340","first-page":"148","article-title":"Quantitative analysis of (18)F-NaF dynamic PET\/CT cannot differentiate malignant from benign lesions in multiple myeloma","volume":"7","author":"Sachpekidis","year":"2017","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0345","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.21873\/anticanres.13304","article-title":"Characterization of bone lesions in myeloma before and during anticancer therapy using (18)F-FDG-PET\/CT and (18)F-NaF-PET\/CT","volume":"39","author":"Nakuz","year":"2019","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0350","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12149-012-0647-7","article-title":"Role of 18F-fluoride PET\/CT in the assessment of multiple myeloma: initial experience","volume":"27","author":"Nishiyama","year":"2013","journal-title":"Ann. Nucl. Med."},{"issue":"2","key":"10.1016\/j.bone.2023.116957_bb0355","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hon.2600","article-title":"Dual-tracer PET\/CT scan after injection of combined [(18) F]NaF and [(18) F]FDG outperforms MRI in the detection of myeloma lesions","volume":"37","author":"Withofs","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.bone.2023.116957_bb0360","article-title":"A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET\/CT, 18F-NaF-PET\/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients","volume":"6","author":"Dyrberg","year":"2017","journal-title":"Acta Radiol. Open"},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051335","article-title":"Can (18)F-NaF PET\/CT before autologous stem cell transplantation predict survival in multiple myeloma?","volume":"12","author":"Sachpekidis","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpet.2022.09.001","article-title":"Emerging role of (18)F-NaF PET\/computed tomographic imaging in osteoporosis: a potential upgrade to the osteoporosis toolbox","volume":"18","author":"Sheppard","year":"2023","journal-title":"PET Clin."},{"issue":"10","key":"10.1016\/j.bone.2023.116957_bb0375","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.95","article-title":"Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma","volume":"7","author":"Wang","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bone.2023.116957_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2021.796357","article-title":"Amino acid and proliferation PET\/CT for the diagnosis of multiple myeloma","volume":"1","author":"Minamimoto","year":"2022","journal-title":"Front. Nucl. Med."},{"key":"10.1016\/j.bone.2023.116957_bb0385","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00259-012-2333-3","article-title":"Clinical value of 11 C-methionine PET\/CT in patients with plasma cell malignancy: comparison with 18 F-FDG PET\/CT","volume":"40","author":"Nakamoto","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041042","article-title":"(18)F-FDG and (11)C-methionine PET\/CT in newly diagnosed multiple myeloma patients: comparison of volume-based PET biomarkers","volume":"12","author":"Morales-Lozano","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.bone.2023.116957_bb0395","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.7150\/thno.20491","article-title":"(11)C-methionine-PET in multiple myeloma: a combined study from two different institutions","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0400","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/neuonc\/nos300","article-title":"[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma","volume":"15","author":"Hutterer","year":"2013","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0405","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5114\/wo.2019.83342","article-title":"18F-fluoro-ethyl-tyrosine (18F-FET) PET\/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study","volume":"23","author":"Czy\u017c","year":"2019","journal-title":"Contemp. Oncol.\/Wsp\u00f3\u0142czesna Onkologia"},{"issue":"12","key":"10.1016\/j.bone.2023.116957_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084840","article-title":"Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology","volume":"8","author":"L\u00fcckerath","year":"2013","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.bone.2023.116957_bb0415","first-page":"331","article-title":"Synthesis and evaluation of [18F] 1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors","volume":"40","author":"Shoup","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bone.2023.116957_bb0420","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2013.08.037","article-title":"Comparative evaluation of transport mechanisms of trans-1-amino-3-[18F] fluorocyclobutanecarboxylic acid and L-[methyl-11C] methionine in human glioma cell lines","volume":"1535","author":"Ono","year":"2013","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0425","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s11307-022-01734-0","article-title":"Comparison of [(18)F]fluciclovine and [(18)F]FDG PET\/CT in newly diagnosed multiple myeloma patients","volume":"24","author":"Stokke","year":"2022","journal-title":"Mol. Imaging Biol."},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0430","first-page":"713","article-title":"Detection of additional primary neoplasms on <sup>18<\/sup>F-Fluciclovine PET\/CT in patients with primary prostate cancer","volume":"63","author":"Parihar","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0435","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13550-022-00876-0","article-title":"Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma","volume":"12","author":"Morath","year":"2022","journal-title":"EJNMMI Res."},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0440","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/153537020623100503","article-title":"Choline transport for phospholipid synthesis","volume":"231","author":"Michel","year":"2006","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"2","key":"10.1016\/j.bone.2023.116957_bb0445","first-page":"96","article-title":"Imaging of prostate cancer with PET\/CT using (18)F-Fluorocholine","volume":"5","author":"Vali","year":"2015","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0450","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.110.077941","article-title":"Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline","volume":"52","author":"Jadvar","year":"2011","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-choline vs. 18F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.bone.2023.116957_bb0460","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study","volume":"43","author":"Cassou-Mounat","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.bone.2023.116957_bb0465","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3390\/diagnostics13091570","article-title":"Multitracer PET\/CT with [18F]Fluorodeoxiglucose and [18F]Fluorocholine in the initial staging of multiple myeloma patients applying the IMPeTus criteria: a pilot study","volume":"13","author":"Garrastachu Zumar\u00e1n","year":"2023","journal-title":"Diagnostics"},{"issue":"8","key":"10.1016\/j.bone.2023.116957_bb0470","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/RLU.0000000000002638","article-title":"Comparison of 11C-choline and 11C-methionine PET\/CT in multiple myeloma","volume":"44","author":"Lapa","year":"2019","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0475","doi-asserted-by":"crossref","first-page":"22188","DOI":"10.1038\/s41598-021-01740-2","article-title":"11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bone.2023.116957_bb0480","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.113.131169","article-title":"11C-acetate PET\/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET\/CT","volume":"55","author":"Ho","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bone.2023.116957_bb0485","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00259-013-2520-x","article-title":"11 C-acetate as a new biomarker for PET\/CT in patients with multiple myeloma: initial staging and postinduction response assessment","volume":"41","author":"Lin","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bone.2023.116957_bb0490","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv. Cancer Res."},{"issue":"12","key":"10.1016\/j.bone.2023.116957_bb0495","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","article-title":"CXCR4-targeted theranostics in oncology","volume":"49","author":"Buck","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"10.1016\/j.bone.2023.116957_bb0500","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET imaging of CXCR4 receptors in cancer by a new optimized ligand","volume":"6","author":"Demmer","year":"2011","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0505","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.114.151647","article-title":"Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor","volume":"56","author":"Herrmann","year":"2015","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0510","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68Ga] Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma-comparison to [18F] FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.bone.2023.116957_bb0515","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3389\/fonc.2019.00770","article-title":"CXCR4-directed imaging in solid tumors","volume":"9","author":"Werner","year":"2019","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.bone.2023.116957_bb0520","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.120.257279","article-title":"Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET\/CT","volume":"62","author":"Duell","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.bone.2023.116957_bb0525","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7150\/thno.21397","article-title":"Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics","volume":"8","author":"Habringer","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0530","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0535","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [(18)F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"1136","key":"10.1016\/j.bone.2023.116957_bb0540","doi-asserted-by":"crossref","first-page":"20211272","DOI":"10.1259\/bjr.20211272","article-title":"Imaging CXCR4 receptors expression for staging multiple myeloma by using (68)Ga-Pentixafor PET\/CT: comparison with (18)F-FDG PET\/CT","volume":"95","author":"Shekhawat","year":"2022","journal-title":"Br. J. Radiol."},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0545","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201404698","article-title":"In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma","volume":"7","author":"Philipp-Abbrederis","year":"2015","journal-title":"EMBO Mol. Med."},{"issue":"supplement 1","key":"10.1016\/j.bone.2023.116957_bb0550","first-page":"18","article-title":"<sup>68<\/sup>Ga-pentixafor PET\/CT in the visual and quantitative evaluation of multiple myeloma: a comparison to <sup>18<\/sup>F-FDG PET\/CT imaging","volume":"60","author":"Pan","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.bone.2023.116957_bb0555","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082333","article-title":"18F-FDG, 11C-methionine, and 68Ga-Pentixafor PET\/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bone.2023.116957_bb0560","first-page":"210","article-title":"Evaluation of chemokine Receptor-4 expression by 68Ga\u2013Pentixafor PET\/CT in patients with multiple myeloma","volume":"32","author":"Ozkan","year":"2019","journal-title":"Int. J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bone.2023.116957_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061467","article-title":"ImmunoPET in multiple myeloma-what? So what? Now what?","volume":"12","author":"Bailly","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bone.2023.116957_bb0570","series-title":"Seminars in Hematology","first-page":"22","article-title":"Functional imaging methods for assessment of minimal residual disease in multiple myeloma: current status and novel immunoPET based methods","author":"Pandit-Taskar","year":"2018"},{"issue":"7","key":"10.1016\/j.bone.2023.116957_bb0575","first-page":"741","article-title":"Copper 64\u2013labeled daratumumab as a PET\/CT imaging tracer for multiple myeloma","volume":"131","author":"Caserta","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0580","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-targeted Immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.bone.2023.116957_bb0585","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s00259-021-05218-1","article-title":"ImmunoPET imaging of multiple myeloma with [(68)Ga]Ga-NOTA-Nb1053","volume":"48","author":"Wang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"supplement 1","key":"10.1016\/j.bone.2023.116957_bb0590","first-page":"62","article-title":"Molecular imaging of multiple myeloma targeting CD46 using ImmunoPET","volume":"62","author":"Wang","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.bone.2023.116957_bb0595","article-title":"Molecular imaging with 3\u2032-deoxy-3\u2032[(18)F]-Fluorothymidine ((18)F-FLT) PET\/CT for early response to targeted therapies in sarcomas: a pilot study","volume":"10","author":"Kairemo","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0600","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-018-0383-7","article-title":"Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET\/CT imaging","volume":"8","author":"Sachpekidis","year":"2018","journal-title":"EJNMMI Res."},{"issue":"2","key":"10.1016\/j.bone.2023.116957_bb0605","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.220749","article-title":"FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.bone.2023.116957_bb0610","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/tomography8010024","article-title":"Comparison of [68Ga]-FAPI PET\/CT and [18F]-FDG PET\/CT in multiple myeloma: clinical experience","volume":"8","author":"Elboga","year":"2022","journal-title":"Tomography"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223002909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223002909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:07:23Z","timestamp":1757614043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328223002909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":123,"alternative-id":["S8756328223002909"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2023.116957","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of conventional and novel PET radiotracers in assessment of myeloma bone disease","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2023.116957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116957"}}